Targeted Agents: Tyrosine Kinase Inhibitors and Monoclonal Antibodies against EGFR and VEGF

This program has expired; CME credits no longer available.
Learn the biologic implications of having an EGFR mutation detected in a NSCLC tumor and discuss the recommendation to consider screening for this mutation at the time of diagnosis.
Duration
August 12, 2009 until August 12, 2010
Credits
Maximum of 1.0 AMA PRA Category 1 Credits™
Faculty
Jennifer Temel, MD | Panagiotis M. Fidias, MD | Jeffrey A. Engelman, MD, PhD

This course is not part of OncologySTAT.
By clicking the button below you will be leaving this website.


Community CommentsTotal comments to date:

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration